Proton Pump Inhibitors: To use or not to use... That is the Question!

RELEASE DATE: April 16, 2016

SLIDE SET FACULTY
Chair:
Jennifer R Lightdale, MD, MPH
Professor of Pediatrics
University of Massachusetts Medical School
Worcester, MA

FACULTY:
Carlo Di Lorenzo, MD
Professor of Pediatrics
The Ohio State University
Nationwide Children's Hospital
Columbus, OH

Jose Garza, MD
Assistant Professor of Pediatrics
Children's Ctr for Digestive Health Care, LLC
Atlanta, GA

Benjamin D. Gold, MD
Professor of Pediatrics and Microbiology
Children's Ctr for Digestive Health Care, LLC
Atlanta, GA

Rachel Rosen, MD
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA

CME REVIEWER:
Henry Lin, MD
Assistant Professor of Pediatrics
University of Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, PA

INTRODUCTION:
There is a need for ongoing education of both general pediatricians and pediatric gastroenterologists who care for pediatric patients with gastroesophageal reflux and its related disorders. There is increasing pressure to ensure appropriate management, including diagnostic and therapeutic strategies that minimize over- and under-utilization of testing and treatment. This program will arm the physician with essential education to ensure clarity surrounding current indications for use of proton pump inhibitors in children, as well as a growing understanding of risks associated with their use.

TARGET AUDIENCE:
This activity is designed for pediatric and adult primary care physicians who are interested in treating children and young adults with gastroesophageal reflux and its related disorders.

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:

- Differentiate Non-Erosive Reflux Disease (NERD) from Erosive Reflux Disease (ERD).
- Functional Heartburn and Hypersensitive Esophagus in regard to the physiological mechanisms are foreign of the above, as well as in diagnostic approach and treatment.
- Understand the pathophysiological basis for the most frequently described extra-esophageal associations with reflux disease, the biological plausibility for these associations, as well as when it might be appropriate to use APh for extra-esophageal conditions associated with reflux.
- Understand clear indications for when PPIs should be prescribed, as well as what to do when PPIs don't work.
- Understand the risks of treatment, why, when and how to stop treatment, as well as what happens if you do not stop treatment.

PHYSICIANS:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the NASPGHAN Foundation. NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA STATEMENT:
NASPGHAN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

STATEMENT OF DISCLOSURE:
All locally, speakers, planners, abstract reviewers, moderators, authors, consultants, and administrative staff participating in the continuing medical education programs sponsored by NASPGHAN are expected to disclose to the program audience any/all financial relationships related to the content of their presentations. Accordingly, the NASPGHAN staff has reported no financial relationships with any commercial interests related to the content of this educational activity.

Jennifer R Lightdale, MD is a consultant for Covidien, Perrigo and Medison.
Carlo Di Lorenzo, MD is a consultant for QDL, Inc. and Espon Associates.
Jose Garza, MD has nothing to disclose.
Benjamin D. Gold, MD is Scientific/Medical Advisory Board Member for A.M. Johnson & P.H.D., Nestle Nutrition USA, Consultant for Nutricia North America, Prometheus Laboratories, and Horizon Pharma.
Rachel Rosen, MD has nothing to disclose.
Henry Lin, MD has nothing to disclose.
Paul Sinclair has nothing to disclose.
Amy Mancini has nothing to disclose.
Rick Weimer has nothing to disclose.

In accordance with ACCME Standards for Commercial Support of CME, NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition implemented mechanisms to identify and resolve conflicts of interest for all individuals in a position to control the CME activity.

To resolve identified conflicts of interest, the educational content was reviewed by a 2-year member of the NASPGHAN Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

OCTOBER 2016 NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition.

©Copyright 2016 NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition.